ArticleFrontiers in oncology2021

Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer.

Wanrui Lv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.